Nchi: Ayalandi
Lugha: Kiingereza
Chanzo: HPRA (Health Products Regulatory Authority)
ONDANSETRON HYDROCHLORIDE
Novartis Pharmaceuticals UK Ltd
A04AA01
ONDANSETRON HYDROCHLORIDE
4/2 Mg/Ml
Solution for Inj/Inf
Product subject to prescription which may not be renewed (A)
Serotonin (5HT3) antagonists
Authorised
2016-01-22
PACKAGE LEAFLET: INFORMATION FOR THE USER ZOFRAN® 4 MG/2 ML (OR 8MG/4 ML) SOLUTION FOR INJECTION OR INFUSION ONDANSETRON (AS HYDROCHLORIDE DIHYDRATE) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions about your illness or your medicine, ask your doctor, nurse or pharmacist. If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1 What Zofran Solution for Injection or Infusion is and what it is used for 2 What you need to know before you have Zofran Solution for Injection or Infusion 3 How to have Zofran Solution for Injection or Infusion 4 Possible side effects 5 How to store Zofran Solution for Injection or Infusion 6 Contents of the pack and other information 1 WHAT ZOFRAN SOLUTION FOR INJECTION OR INFUSION IS AND WHAT IT IS USED FOR Zofran Solution for Injection or Infusion (called ‘Zofran injection’ in this leaflet) contains a medicine called ondansetron (as hydrochloride dihydrate). This belongs to a group of medicines called anti-emetics. Zofran injection is used for: preventing nausea and vomiting caused by chemotherapy [http://www.netdoctor.co.uk/medicines/effect/cancer.shtml]or radiotherapy for cancer [http://www.netdoctor.co.uk/cancer/index.shtml]in ADULTS preventing and treating nausea and vomiting after surgery in ADULTS preventing nausea and vomiting caused Soma hati kamili
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zofran 4mg/2ml Solution for Injection or Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 2mg ondansetron as hydrochloride dihydrate.(4mg/2ml) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection or infusion. Clear, colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ADULTS Zofran Solution for Injection or Infusion is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran Solution for Injection or Infusion is also indicated for the prevention and treatment of post-operative nausea and vomiting. PAEDIATRIC POPULATION Zofran Solution for Injection or Infusion is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy in children and adolescents aged from 6 months to 17 years. IV Zofran injection is indicated for the prevention or treatment of post-operative nausea and vomiting in children and adolescents aged from 1 month to 17 years. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Zofran is also available for oral and rectal use to allow the route of administration and dosing to be flexible. CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING (CINV AND RINV) The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection of dose regimen should be determined by the severity of the emetogenic challenge. _CINV AND RINV IN ADULTS:-_ The dose range of Zofran Solution for Injection or Infusion is 8 to 32 mg a day and selected as shown below. _Emetogenic Chemotherapy and Radiotherapy:_ For most patients receiving emetogenic chemotherapy or radiotherapy, Zofran 8mg should be administered as a slow intravenous injection (in not less than 30 seconds) or intramuscular injection, immediately before treatment, followed by 8mg orally twelve hourly. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Soma hati kamili